Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00077142 · ClinicalTrials.gov registry record · Phase 1
TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT00077142: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00077142 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 37 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00077142, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
RATIONALE: TAC-101 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: This phase I/II trial is studying the side effects and best dose of TAC-101 and to see how well it works in treating patients with advanced hepatocellular carcinoma (liver cancer).
Interventions
- DRUG TAC-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2001-04 |
| Est. Completion | 2005-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00077142
The ClinicalTrials.gov registry entry for NCT00077142 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TAC-101 is the first listed.
NCT00077142 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00077142 about?
NCT00077142 is a clinical study titled "TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)". RATIONALE: TAC-101 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: This phase I/II trial is studying the side effects and best dose of TAC-101 and to see how well it works in treating patients with advanced hepatocellular carcinoma (liver cancer).
What is the current status of trial NCT00077142?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2001-04. Estimated completion is 2005-08.
What interventions are being tested in trial NCT00077142?
The interventions under investigation include: TAC-101 (DRUG).
Who is sponsoring clinical trial NCT00077142?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.